Suppressing estrogen to treat lung cancer

Patel Lung cancer is the leading cause of death in women, and the hormone estrogen has been shown to play a role in the growth of lung tumors.

With Masonic support, Manish Patel, D.O., part of the U’s hematology, oncology, and transplantation faculty is exploring the impact of estrogen signaling on lung cancer immunotherapy.

So far, Patel’s team has found that while immunotherapy has benefits, estrogen receptors in lung tumors might interfere with its effectiveness. They are now exploring whether a breast cancer drug that suppresses estrogen, called exemestane, might increase the potency of immunotherapy against lung cancer. Their next big step will be to launch a clinical trial that tests this combination treatment.

Support from Minnesota Masonic Charities has allowed us to gain insight into how estrogen signaling might impact a woman’s response to lung cancer immunotherapy.

 

Related

Sloan Featured
With Masonic Scholar support, Lindsey Sloan, radiation oncology faculty member and one of the University’s newest recruits, is dedicating her work in... Read more
Erickson featured
Clear cell ovarian cancer (CCOC) is a subtype of ovarian cancer with high rates of recurrence and resistance to chemotherapy.
Julie Ostrander
Proteins play an essential role in regulating how the human body functions. But sometimes they stop working as they should, causing cells to grow out... Read more